Medić Brkić, Branislava

Link to this page

Authority KeyName Variants
orcid::0000-0001-7012-6766
  • Medić Brkić, Branislava (1)
  • Medić Brkić. Branislava (1)
  • Medić-Brkić, Branislava (1)
Projects

Author's Bibliography

TRPV1: Ciljno mesto dejstva lekova u terapiji različitih stanja

Medić Brkić, Branislava; Savić Vujović, Katarina; Srebro, Dragana; Vučković, Sonja

(Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo, 2022)

TY  - CHAP
AU  - Medić Brkić, Branislava
AU  - Savić Vujović, Katarina
AU  - Srebro, Dragana
AU  - Vučković, Sonja
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1810
AB  - Nobelova nagrada za fiziologiju i medicinu za 2021. dodeljena je naučnicima koji su identifikovali receptore
za temperaturu i dodir. Da bi sproveli ovo ispitivanje, istraživači su koristili kapsaicin, jedinjenje koje
čili paprici daje toplotu, kako bi otkrili receptore koji omogućavaju ljudima da osete “gorući” ukus čilija.
Pokazano je da se transient receptor potential vanilloid 1 (TRPV1), koji predstavlja jonski kanal prisutan na
senzornim neuronima, otvara u prisustvu kapsaicina ili toplote, propuštajući naelektrisane jone kalcijuma
u ćeliju. Takav priliv kalcijuma pokreće električne signale koji se šalju u mozak da upozore na toplotu. TRPV1
se nalazi u somatosenzornom sistemu i služi kao multimodalni senzor različitih štetnih stimulusa.
Brojne farmakološke i genetičke studije su potvrdile TRPV1 kao terapeutsku metu u nekoliko pretkliničkih
modela hroničnog bola, uključujući maligni, neuropatski, postoperativni i mišićno-skeletni bol.
Pored toga, ekspresija TRPV1 se takođe primećuje na ne-neuronskim lokalizacijama, kao što su epitel bešike
i pluća, ćelije kohlee u uhu. Stoga, lekovi koji mogu da modulišu aktivnost kanala TRPV1 mogu biti korisni
za lečenje različitih stanja u rasponu od hroničnog bola do gubitka sluha. Iako je utvrđeno da
antagonisti TRPV1 mogu predstavljati važan dodatak terapiji bola, njihova klinička upotreba je i dalje ograničena
značajnim neželjenim efektima, kao što je hipertermija.
U ovom radu ćemo opisati najvažnije uloge TRPV1 u fiziološkim i patofiziološkim procesima i predstaviti
najperspektivnije lekove koji deluju preko TRPV1.
AB  - The 2021. Nobel Prize in Physiology or Medicine was awarded to scientists who have identified receptors
for temperature and touch. In order to conduct this examination, researchers used capsaicin, the
compound that gives chili peppers their heat, to discover receptor proteins that allow people to feel chili’s
burn. It is shown that transient receptor potential vanilloid 1 (TRPV1), which represents an ion channel
present on sensory neurons, opens when it encounters capsaicin or heat, allowing charged calcium ions
into the cell. That flood of calcium triggers electrical signals that are sent to the brain to warn of heat.
TRPV1 is found in the somatosensory system and serves as a multimodal sensor of different noxious stimuli.
Numerous pharmacological and genetic studies have validated TRPV1 as a therapeutic target in several
preclinical models of chronic pain, including cancer, neuropathic, postoperative and musculoskeletal
pain. Additionally, expression of TRPV1 is also observed in non-neuronal sites such as the epithelium
of bladder and lungs, cells of the cochlea. Therefore, drugs which could modulate TRPV1 channel activity
could be useful for the treatment of conditions ranging from chronic pain to hearing loss. While antagonists
of TRPV1 were found to be a valuable addition to therapy of pain, their clinical use has still been limited
by significant side effects, such as hyperthermia.
In this review, we will describe the most important roles of TRPV1 in physiological and pathophysiological
processes and present the most promising TRPV1-targeted drugs.
PB  - Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo
T2  - Trendovi u molekularnoj Biologiji
T1  - TRPV1: Ciljno mesto dejstva lekova u terapiji različitih stanja
T1  - TRPV1: A Promising drug target for the treatment of various conditions
EP  - 30
IS  - 2
SP  - 15
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1810
ER  - 
@inbook{
author = "Medić Brkić, Branislava and Savić Vujović, Katarina and Srebro, Dragana and Vučković, Sonja",
year = "2022",
abstract = "Nobelova nagrada za fiziologiju i medicinu za 2021. dodeljena je naučnicima koji su identifikovali receptore
za temperaturu i dodir. Da bi sproveli ovo ispitivanje, istraživači su koristili kapsaicin, jedinjenje koje
čili paprici daje toplotu, kako bi otkrili receptore koji omogućavaju ljudima da osete “gorući” ukus čilija.
Pokazano je da se transient receptor potential vanilloid 1 (TRPV1), koji predstavlja jonski kanal prisutan na
senzornim neuronima, otvara u prisustvu kapsaicina ili toplote, propuštajući naelektrisane jone kalcijuma
u ćeliju. Takav priliv kalcijuma pokreće električne signale koji se šalju u mozak da upozore na toplotu. TRPV1
se nalazi u somatosenzornom sistemu i služi kao multimodalni senzor različitih štetnih stimulusa.
Brojne farmakološke i genetičke studije su potvrdile TRPV1 kao terapeutsku metu u nekoliko pretkliničkih
modela hroničnog bola, uključujući maligni, neuropatski, postoperativni i mišićno-skeletni bol.
Pored toga, ekspresija TRPV1 se takođe primećuje na ne-neuronskim lokalizacijama, kao što su epitel bešike
i pluća, ćelije kohlee u uhu. Stoga, lekovi koji mogu da modulišu aktivnost kanala TRPV1 mogu biti korisni
za lečenje različitih stanja u rasponu od hroničnog bola do gubitka sluha. Iako je utvrđeno da
antagonisti TRPV1 mogu predstavljati važan dodatak terapiji bola, njihova klinička upotreba je i dalje ograničena
značajnim neželjenim efektima, kao što je hipertermija.
U ovom radu ćemo opisati najvažnije uloge TRPV1 u fiziološkim i patofiziološkim procesima i predstaviti
najperspektivnije lekove koji deluju preko TRPV1., The 2021. Nobel Prize in Physiology or Medicine was awarded to scientists who have identified receptors
for temperature and touch. In order to conduct this examination, researchers used capsaicin, the
compound that gives chili peppers their heat, to discover receptor proteins that allow people to feel chili’s
burn. It is shown that transient receptor potential vanilloid 1 (TRPV1), which represents an ion channel
present on sensory neurons, opens when it encounters capsaicin or heat, allowing charged calcium ions
into the cell. That flood of calcium triggers electrical signals that are sent to the brain to warn of heat.
TRPV1 is found in the somatosensory system and serves as a multimodal sensor of different noxious stimuli.
Numerous pharmacological and genetic studies have validated TRPV1 as a therapeutic target in several
preclinical models of chronic pain, including cancer, neuropathic, postoperative and musculoskeletal
pain. Additionally, expression of TRPV1 is also observed in non-neuronal sites such as the epithelium
of bladder and lungs, cells of the cochlea. Therefore, drugs which could modulate TRPV1 channel activity
could be useful for the treatment of conditions ranging from chronic pain to hearing loss. While antagonists
of TRPV1 were found to be a valuable addition to therapy of pain, their clinical use has still been limited
by significant side effects, such as hyperthermia.
In this review, we will describe the most important roles of TRPV1 in physiological and pathophysiological
processes and present the most promising TRPV1-targeted drugs.",
publisher = "Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo",
journal = "Trendovi u molekularnoj Biologiji",
booktitle = "TRPV1: Ciljno mesto dejstva lekova u terapiji različitih stanja, TRPV1: A Promising drug target for the treatment of various conditions",
pages = "30-15",
number = "2",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1810"
}
Medić Brkić, B., Savić Vujović, K., Srebro, D.,& Vučković, S.. (2022). TRPV1: Ciljno mesto dejstva lekova u terapiji različitih stanja. in Trendovi u molekularnoj Biologiji
Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo.(2), 15-30.
https://hdl.handle.net/21.15107/rcub_imagine_1810
Medić Brkić B, Savić Vujović K, Srebro D, Vučković S. TRPV1: Ciljno mesto dejstva lekova u terapiji različitih stanja. in Trendovi u molekularnoj Biologiji. 2022;(2):15-30.
https://hdl.handle.net/21.15107/rcub_imagine_1810 .
Medić Brkić, Branislava, Savić Vujović, Katarina, Srebro, Dragana, Vučković, Sonja, "TRPV1: Ciljno mesto dejstva lekova u terapiji različitih stanja" in Trendovi u molekularnoj Biologiji, no. 2 (2022):15-30,
https://hdl.handle.net/21.15107/rcub_imagine_1810 .

Biomarkers of Uremic Cardiotoxicity

Stopić, Bojan; Dragičević, Sandra; Medić-Brkić, Branislava; Nikolić, Aleksandra; Stojanović, Marko; Budisavljević, Sreten; Dimković, Nada

(MDPI, Basel, 2021)

TY  - JOUR
AU  - Stopić, Bojan
AU  - Dragičević, Sandra
AU  - Medić-Brkić, Branislava
AU  - Nikolić, Aleksandra
AU  - Stojanović, Marko
AU  - Budisavljević, Sreten
AU  - Dimković, Nada
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1463
AB  - Cardiovascular (CV) morbidity and mortality increase along with the progression of chronic kidney disease (CKD). The potential novel biomarkers of cardiotoxicity have been tested with the aim of the early detection of patients at high CV risk, and among them are markers of inflammation, oxidative stress, acute renal injury, and microRNAs. The study analyzed biomarkers in non-dialysis-dependent (NDD; stage 3a-4 CKD) and dialysis-dependent (DD) CKD patients. The prospective cohort study included 87 patients who were followed for 18 months, during which period newly occurred CV events were recorded. Cox regression analysis confirmed serum albumin, urea, interventricular septum thickness diameter (IVST), the use of calcium antagonist, and erythropoiesis-stimulating agent to be significant predictors of CV outcome. No significant difference was observed in biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, and KIM-1), and miR-133a, in regards to the presence/absence of CV event, CV death, and left ventricular hypertrophy. Serum albumin, urea, IVST, and the use of calcium antagonist and erythropoiesis-stimulating agents were confirmed to be factors associated with CV events in CKD patients. Apart from traditional risk factors, new research is needed to define novel and reliable biomarkers of cardiotoxicity in CKD patients.
PB  - MDPI, Basel
T2  - Toxins
T1  - Biomarkers of Uremic Cardiotoxicity
IS  - 9
VL  - 13
DO  - 10.3390/toxins13090639
ER  - 
@article{
author = "Stopić, Bojan and Dragičević, Sandra and Medić-Brkić, Branislava and Nikolić, Aleksandra and Stojanović, Marko and Budisavljević, Sreten and Dimković, Nada",
year = "2021",
abstract = "Cardiovascular (CV) morbidity and mortality increase along with the progression of chronic kidney disease (CKD). The potential novel biomarkers of cardiotoxicity have been tested with the aim of the early detection of patients at high CV risk, and among them are markers of inflammation, oxidative stress, acute renal injury, and microRNAs. The study analyzed biomarkers in non-dialysis-dependent (NDD; stage 3a-4 CKD) and dialysis-dependent (DD) CKD patients. The prospective cohort study included 87 patients who were followed for 18 months, during which period newly occurred CV events were recorded. Cox regression analysis confirmed serum albumin, urea, interventricular septum thickness diameter (IVST), the use of calcium antagonist, and erythropoiesis-stimulating agent to be significant predictors of CV outcome. No significant difference was observed in biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, and KIM-1), and miR-133a, in regards to the presence/absence of CV event, CV death, and left ventricular hypertrophy. Serum albumin, urea, IVST, and the use of calcium antagonist and erythropoiesis-stimulating agents were confirmed to be factors associated with CV events in CKD patients. Apart from traditional risk factors, new research is needed to define novel and reliable biomarkers of cardiotoxicity in CKD patients.",
publisher = "MDPI, Basel",
journal = "Toxins",
title = "Biomarkers of Uremic Cardiotoxicity",
number = "9",
volume = "13",
doi = "10.3390/toxins13090639"
}
Stopić, B., Dragičević, S., Medić-Brkić, B., Nikolić, A., Stojanović, M., Budisavljević, S.,& Dimković, N.. (2021). Biomarkers of Uremic Cardiotoxicity. in Toxins
MDPI, Basel., 13(9).
https://doi.org/10.3390/toxins13090639
Stopić B, Dragičević S, Medić-Brkić B, Nikolić A, Stojanović M, Budisavljević S, Dimković N. Biomarkers of Uremic Cardiotoxicity. in Toxins. 2021;13(9).
doi:10.3390/toxins13090639 .
Stopić, Bojan, Dragičević, Sandra, Medić-Brkić, Branislava, Nikolić, Aleksandra, Stojanović, Marko, Budisavljević, Sreten, Dimković, Nada, "Biomarkers of Uremic Cardiotoxicity" in Toxins, 13, no. 9 (2021),
https://doi.org/10.3390/toxins13090639 . .
1
3
4

Is miR-133a marker of progressive chronic kidney disease?

Stopić, Bojan; Dragičević, Sandra; Medić Brkić. Branislava; Nikolić, Aleksandra; Budisavljević, Sreten; Marković Nikolić, Natasa; Dimković, Nada

(Oxford University Press, 2019)

TY  - CONF
AU  - Stopić, Bojan
AU  - Dragičević, Sandra
AU  - Medić Brkić. Branislava
AU  - Nikolić, Aleksandra
AU  - Budisavljević, Sreten
AU  - Marković Nikolić, Natasa
AU  - Dimković, Nada
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2080
AB  - Chronic kidney disease (CKD) is associated with a high incidence of cardiovascular (CV) disease and numerous risk factor have been implicated to play a role.  Recent studies have shown that the levels of various microRNAs in the serum of patients with CKD have been altered and there are reports that miR-133a serum levels correlated with left ventricular hypertrophy in hemodialysis patients.The aim of this study was to investigate association between circulating miR-133a levels and development of de novo CV events in patients with CKD stage 3-5HD.METHODS: This study included 51 patients with diagnosed CKD and 7 healthy individuals as controls. According to the estimated glomerular filtration ratio (eGFR) patients were divided into three equal subgroups (n=17): patients with CKD stage 3b, 4, and 5HD.  The level of miR-133a was measured in serum by quantitative real-time PCR. Echo parameters were measured by cardiac ultrasound at the beginning and after 12 months of follow-up. The following CV events were reported during 18 months of follow-up: cardiac death, myocardial infarction, cerebrovascular insult, exacerbation of existing and newly discovered angina pectoris and peripheral arterial disease.
PB  - Oxford University Press
C3  - Nephrology Dialysis Transplantation, 56th ERA-EDTA Congress Abstracts
T1  - Is miR-133a marker of progressive chronic kidney disease?
IS  - Supplement_1
SP  - FP177
VL  - 34
DO  - 10.1093/ndt/gfz106.FP177
ER  - 
@conference{
author = "Stopić, Bojan and Dragičević, Sandra and Medić Brkić. Branislava and Nikolić, Aleksandra and Budisavljević, Sreten and Marković Nikolić, Natasa and Dimković, Nada",
year = "2019",
abstract = "Chronic kidney disease (CKD) is associated with a high incidence of cardiovascular (CV) disease and numerous risk factor have been implicated to play a role.  Recent studies have shown that the levels of various microRNAs in the serum of patients with CKD have been altered and there are reports that miR-133a serum levels correlated with left ventricular hypertrophy in hemodialysis patients.The aim of this study was to investigate association between circulating miR-133a levels and development of de novo CV events in patients with CKD stage 3-5HD.METHODS: This study included 51 patients with diagnosed CKD and 7 healthy individuals as controls. According to the estimated glomerular filtration ratio (eGFR) patients were divided into three equal subgroups (n=17): patients with CKD stage 3b, 4, and 5HD.  The level of miR-133a was measured in serum by quantitative real-time PCR. Echo parameters were measured by cardiac ultrasound at the beginning and after 12 months of follow-up. The following CV events were reported during 18 months of follow-up: cardiac death, myocardial infarction, cerebrovascular insult, exacerbation of existing and newly discovered angina pectoris and peripheral arterial disease.",
publisher = "Oxford University Press",
journal = "Nephrology Dialysis Transplantation, 56th ERA-EDTA Congress Abstracts",
title = "Is miR-133a marker of progressive chronic kidney disease?",
number = "Supplement_1",
pages = "FP177",
volume = "34",
doi = "10.1093/ndt/gfz106.FP177"
}
Stopić, B., Dragičević, S., Medić Brkić. Branislava, Nikolić, A., Budisavljević, S., Marković Nikolić, N.,& Dimković, N.. (2019). Is miR-133a marker of progressive chronic kidney disease?. in Nephrology Dialysis Transplantation, 56th ERA-EDTA Congress Abstracts
Oxford University Press., 34(Supplement_1), FP177.
https://doi.org/10.1093/ndt/gfz106.FP177
Stopić B, Dragičević S, Medić Brkić. Branislava, Nikolić A, Budisavljević S, Marković Nikolić N, Dimković N. Is miR-133a marker of progressive chronic kidney disease?. in Nephrology Dialysis Transplantation, 56th ERA-EDTA Congress Abstracts. 2019;34(Supplement_1):FP177.
doi:10.1093/ndt/gfz106.FP177 .
Stopić, Bojan, Dragičević, Sandra, Medić Brkić. Branislava, Nikolić, Aleksandra, Budisavljević, Sreten, Marković Nikolić, Natasa, Dimković, Nada, "Is miR-133a marker of progressive chronic kidney disease?" in Nephrology Dialysis Transplantation, 56th ERA-EDTA Congress Abstracts, 34, no. Supplement_1 (2019):FP177,
https://doi.org/10.1093/ndt/gfz106.FP177 . .